Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

BAVARIAN NORDIC A/S

WKN: 917165  ISIN: DK0015998017  Ticker-Symbol: BV3 
Aktie:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BAVARIAN NORDIC A/S Chart 1 Jahr
1-Woche-Intraday-Chart
BAVARIAN NORDIC A/S 1-Woche-Intraday-Chart

Aktuelle News zur BAVARIAN NORDIC Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
22.05. 7
KVISTGÅRD, Denmark, May 22, 2012 /PRNewswire/ -- Bavarian Nordic A/S (NASDAQ OMX: BAVA) announced today that the U.S. Department of Health and Human Services has supported the initiation of an expanded...
Mehr lesen zu:
U.S. Government Supports Phase 3 Study of Bavarian Nordic's Smallpox Vaccine
22.05. 58
KVISTGAARD, Denmark, May 22, 2012 - Bavarian Nordic A/S (OMX: BAVA) today publishes its first quarter 2012 results, showing a DKK 100 million improvement in income before tax compared to 2011. Bavarian...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic A/S - Interim Report for the period 1 January to 31 March 2012
18.05. 50
KVISTGAARD, Denmark, May 18, 2012 - Bavarian Nordic A/S (OMX: BAVA) today announced that new interim data from an ongoing, Phase 2 randomized trial of the Company's PROSTVAC® therapeutic cancer vaccine...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic to Report New PROSTVAC® Clinical Data at the American Society of Clinical Oncology Annual Meeting
14.05. 43
KVISTGAARD, Denmark - May 14, 2012 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2012 first quarterly results on Tuesday, May 22, 2012. The company will host a conference call at 2:00 pm CET...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic to Host First Quarter 2012 Results Conference Call
16.04. 36
Kvistgård, Denmark, April 16, 2012 - Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the results as follows:                             ...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic A/S - Report on the Results of the Annual General Meeting, held 16 April 2012
10.04. 45
KVISTGAARD, Denmark, April 10, 2012 - Bavarian Nordic A/S (OMX: BAVA) - Following the notice convening the ordinary general meeting, published on 21 March 2012, the board of directors of Bavarian...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic Nominates Peter Kürstein for Election to the Board
21.03. 4
21.03. 24
Pursuant to Article 10 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the ordinary General Meeting to be held on Monday, 16 April 2012 at 16.00 o'clock...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic A/S - Notice Convening Ordinary General Meeting
08.03. 6
08.03. 42
KVISTGAARD, Denmark, March 8, 2012 - Bavarian Nordic A/S (OMX: BAVA) today published its 2011 Annual Report. The 2011 financial statements show improved revenue, result before tax and year-end cash...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic Announces 2011 Full Year Results
02.03. 3
02.03. 34
KVISTGAARD, Denmark - March 2, 2012 - Bavarian Nordic A/S (OMX:  BAVA) announces its 2011 full year results on Thursday, March 8. The company will host a conference call at 3:30 pm CET (9:30 am EST)...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic to Host Full Year 2011 Conference Call
01.03. 2
01.03. 87
KVISTGAARD, Denmark, March 1, 2012 - Bavarian Nordic A/S (OMX: BAVA) announced today that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic Submits a Marketing Application for its Smallpox Vaccine to the European Medicines Agency
23.02. 97
KVISTGAARD, Denmark, February 23, 2012 - Bavarian Nordic A/S (OMX: BAVA) announced today that a newly published study suggests potential synergy of the Company's PROSTVAC® investigational therapeutic...
Mehr lesen zu:
Bavarian Nordic A/S: PROSTVAC® and Ipilimumab Phase 1 Study Supports Rationale for Combining Two Immunotherapies for Prostate Cancer
09.02. 40
KVISTGAARD, Denmark, February 9, 2012 - Bavarian Nordic (NASDAQ OMX: BAVA) announced today that it will present at the 14th Annual BIO CEO & Investor Conference in New York on Tuesday, February 14...
Mehr lesen zu:
Bavarian Nordic A/S: Bavarian Nordic to Present at the 14th Annual BIO CEO & Investor Conference in New York
30.11. 43
As per 2 December 2011 the new shares issued due to conversion of debt will be admitted to trading on NASDAQ OMX Copenhagen. We refer to the announcements published by Bavarian Nordic. ISIN: ...
Mehr lesen zu:
NASDAQ OMX Copenhagen A/S: Bavarian Nordic A/S - change due to conversion of debt
17 Nachrichten in den letzten 6 Monaten